NCT02719743View on ClinicalTrials.gov

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

PHASE2CompletedINTERVENTIONAL
Enrollment

185

Participants

Timeline

Start Date

July 7, 2016

Primary Completion Date

February 13, 2018

Study Completion Date

February 13, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).

All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.

Trial Locations (7)

100

GSK Investigational Site, Taipei

104

GSK Investigational Site, Taipei

333

GSK Investigational Site, Taoyuan District

404

GSK Investigational Site, Taichung

407

GSK Investigational Site, Taichung

10330

GSK Investigational Site, Bangkok

50200

GSK Investigational Site, Chiang Mai

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02719743 - A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age | Biotech Hunter | Biotech Hunter